Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.21% |
| 2 | Technology | 12.9% |
| 3 | Consumer Discretionary | 10.45% |
| 4 | Financials | 8.48% |
| 5 | Industrials | 7.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ESBK
3001
DELISTED
Elmira Savings Bank Elmira NY
ESBK
| $374K | ﹤0.01% |
24,785
-1,300
| -5% | -$19.2K |
|
3002
Global X SuperDividend ETF
SDIV
$1.21B
| $373K | ﹤0.01% |
+7,033
| New | +$362K |
|
3003
Invesco BuyBack Achievers ETF
PKW
$1.8B
| $372K | ﹤0.01% |
5,400
-4,800
| -47% | -$316K |
|
3004
Vanguard Morningstar Value ETF
VTV
$194B
| $372K | ﹤0.01% |
3,100
-2,700
| -47% | -$312K |
|
3005
Optical Cable Corp
OCC
$149M
| $371K | ﹤0.01% |
114,103
-14,100
| -11% | -$44.8K |
|
|
ELSE
3006
DELISTED
Electro-Sensors
ELSE
| $370K | ﹤0.01% |
102,000
+1,200
| +1% | +$4.48K |
|
3007
Invesco Large Cap Value ETF
PWV
$1.79B
| $368K | ﹤0.01% |
+8,900
| New | +$355K |
|
3008
Zedge
ZDGE
$38.6M
| $368K | ﹤0.01% |
239,014
+2,900
| +1% | +$4.96K |
|
3009
Goldgroup Mining Inc.
GORO
$211M
| $367K | ﹤0.01% |
66,200
-682,669
| -91% | -$2.98M |
|
|
XYF
3010
X Financial
XYF
$202M
| $366K | ﹤0.01% |
72,217
+27,779
| +63% | +$157K |
|
3011
Global X Silver Miners ETF NEW
SIL
$4.75B
| $365K | ﹤0.01% |
+11,000
| New | +$329K |
|
3012
Plumas Bancorp
PLBC
$439M
| $364K | ﹤0.01% |
13,780
+2,180
| +19% | +$51.5K |
|
|
COE
3013
51Talk Online Education Group
COE
$121M
| $363K | ﹤0.01% |
9,250
+2,500
| +37% | +$71.5K |
|
3014
ReposiTrak
TRAK
$152M
| $362K | ﹤0.01% |
71,608
+19,208
| +37% | +$98.7K |
|
|
SALM
3015
DELISTED
Salem Media Group, Inc. Class A Common Stock
SALM
| $361K | ﹤0.01% |
250,598
+18,700
| +8% | +$28K |
|
3016
Reinsurance Group of America
RGA
$16.1B
| $359K | ﹤0.01% |
2,200
-2,300
| -51% | -$372K |
|
|
CTEK
3017
DELISTED
CynergisTek, Inc.
CTEK
| $359K | ﹤0.01% |
108,745
-16,479
| -13% | -$49.9K |
|
|
ONCS
3018
DELISTED
OncoSec Medical Incorporated
ONCS
| $359K | ﹤0.01% |
9,024
+4,857
| +117% | +$220K |
|
3019
Assured Guaranty
AGO
$3.29B
| $358K | ﹤0.01% |
7,300
-88,700
| -92% | -$4.24M |
|
|
SURF
3020
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $356K | ﹤0.01% |
189,100
+139,900
| +284% | +$233K |
|
|
TCON
3021
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $355K | ﹤0.01% |
7,576
+1,137
| +18% | +$74.7K |
|
|
JASN
3022
DELISTED
Jason Industries, Inc.
JASN
| $355K | ﹤0.01% |
954,267
+37,896
| +4% | +$9.84K |
|
|
FM
3023
DELISTED
iShares Frontier and Select EM ETF
FM
| $355K | ﹤0.01% |
11,700
+4,381
| +60% | +$127K |
|
3024
Caterpillar
CAT
$393B
| $354K | ﹤0.01% |
2,400
-122,204
| -98% | -$17.1M |
|
3025
iShares MSCI Singapore ETF
EWS
$1.16B
| $354K | ﹤0.01% |
+14,675
| New | +$353K |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.